

UNIVERSITY PHYSICIANS HEALTH PLANS
(University Family Care)

PHARMACY REFERRAL GUIDELINE

NEUPOGEN®

INDICATIONS

Cancer Patients Receiving Myelosuppressive Chemotherapy

Neupogen® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.

Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy

Neupogen® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML.

Cancer Patients Receiving Bone Marrow Transplant

Neupogen® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae; e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation.

Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy

Neupogen® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.

Patients With Severe Chronic Neutropenia

Neupogen® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.

DOSAGE AND ADMINISTRATION

Cancer Patients Receiving Myelosuppressive Chemotherapy

The recommended starting dose of Neupogen® is 5 mcg/kg/day, administered as a single daily injection by SC bolus injection, by short IV infusion (15 to 30 minutes), or by continuous SC or continuous IV infusion. Neupogen® should be administered daily for up to 2 weeks.

Cancer Patients Receiving Bone Marrow Transplant

The recommended dose of Neupogen® following BMT is 10 mcg/kg/day given as an IV infusion of 4 or 24 hours, or as a continuous 24-hour SC infusion.

Peripheral Blood Progenitor Cell Collection and Therapy in Cancer Patients

The recommended dose of Neupogen® for the mobilization of PBPC is 10 mcg/kg/ day SC, either as a bolus or a continuous infusion. Neupogen® should be given for at least 4 days.

Patients With Severe Chronic Neutropenia

Congenital Neutropenia: The recommended daily starting dose is 6 mcg/kg BID SC every day.

Idiopathic or Cyclic Neutropenia: The recommended daily starting dose is 5 mcg/kg as a single injection SC every day.

Pharmacy Guidelines - Neupogen®

-3-

PRIOR AUTH – RN'S

CANDIDATES FOR MED AS ABOVE, PLUS:

- Starting:
- Chemo regimen which will produce > 40% incidence of febrile neutropenia. May also be used in patients with risk factors.
 - Patients with febrile neutropenia at high risk.
 - Patients with AML and ALL following chemo.
 - Patients with ↓ ANC too low for continuation of chemo.

Treat to ANC of 3000 – 4000 after nadir (expected from chemo regimen)

Auth x 7-10 days

OR

7 – 10 days x 3 months if having a series of chemotherapy treatment.

Approved by the Pharmacy and Therapeutics Committee 5/02; Reviewed 12/03, 12/05, 6/06, 1/08, 5/09